BAK Earnings

BAK reported its earnings on 2025-11-06, showcasing a revenue of 0.00 against an estimate of 3.00B, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.48 by 0% . The stock experienced a -3.98% price change on the earnings day and a 19.92% change over the next five days, reflecting market reactions to the results.

Following BAK's earnings announcement on 2025-11-06, the stock price moved by -3.98% on the day of the release. Over the subsequent five days, it saw a 19.92% change. Historically, BAK's stock price tends to shift by an average of +1.72% in the 10 days leading up to earnings and +0.87% in the 10 days following, providing insight into potential market.

For 2025/Q3, analysts estimate BAK’s annual revenue to reach 17.00B, while the EPS is projected at -1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -1.68% and EPS estimates Revise Upward by 3.06% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between BAK's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -1.68%, while EPS estimates moved Revise Upward by 3.06% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, BAK's stock price typically moves by +1.72% in the 10 days before its earnings and +0.87% in the 10 days after. For the upcoming 2025/Q3 earnings, analysts expect an EPS of -1.00 and revenue of 17.00B.

The earnings call summary reveals several concerns: high cash consumption, weak resin volumes, and challenges in Europe. The Q&A section adds more uncertainty, with management unable to confirm restructuring plans or contract signings, and projecting a subdued petrochemical cycle. While there are some positive long-term projects like Transform Rio and PRESIQ, immediate financial health appears strained, and market sentiment is likely negative. The company's market cap suggests moderate volatility, leading to a prediction of a negative stock price movement of -2% to -8% over the next two weeks.